[go: up one dir, main page]

AR028732A1 - Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. - Google Patents

Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.

Info

Publication number
AR028732A1
AR028732A1 ARP010102885A ARP010102885A AR028732A1 AR 028732 A1 AR028732 A1 AR 028732A1 AR P010102885 A ARP010102885 A AR P010102885A AR P010102885 A ARP010102885 A AR P010102885A AR 028732 A1 AR028732 A1 AR 028732A1
Authority
AR
Argentina
Prior art keywords
different
inhibitors
glutaril
coenzyme
reductase
Prior art date
Application number
ARP010102885A
Other languages
English (en)
Inventor
Jeffrey A Robl
Bang-Chi Chen
Chong-Qing Sun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR028732A1 publication Critical patent/AR028732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Se proporcionan compuestos de la siguiente estructura que son inhibidores de HMG CoA reductasa y por lo tanto son activos para inhibir la biosíntesis de colesterol, modular los lípidos en suero sanguíneo, por ejemplo, disminuir el colesterol LDL o incrementar el colesterol HDL, y tratar la hiperlipidemia, dislipidemia, terapia de sustitucion de hormonas, hipercolesterolemia, hipertrigliceridemia y arteriosclerosis así como enfermedad de Alzheimer y osteoporosis. Formula 1 y sales farmacéuticamente aceptables de los mismos Z es 2 o 3; n es 0 o 1; x es 0, 1, 2, 3 o 4; y es 0, 1, 2, 3 o 4, con la condicion de que por lo menos uno de x e y sea diferente de 0, y opcionalmente uno o más carbonos de (CH2)x o de (CH2)y junto con carbonos adicionales forman un anillo espirocíclico de 3 a 7 miembros; R1 y R2 son iguales o diferentes y se seleccionan independientemente de alquilo, arilalquilo, cicloalquilo, alquenilo, cicloalquenilo, arilo, heteroarilo o cicloheteroalquilo, R3 es H o alquilo inferior; R4 y R7 son como se definen en la descripcion.
ARP010102885A 2000-06-15 2001-06-15 Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa. AR028732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21159400P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
AR028732A1 true AR028732A1 (es) 2003-05-21

Family

ID=22787566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102885A AR028732A1 (es) 2000-06-15 2001-06-15 Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.

Country Status (20)

Country Link
US (1) US20020028826A1 (es)
EP (1) EP1294696A2 (es)
JP (1) JP2004503541A (es)
KR (1) KR20030010720A (es)
CN (1) CN1436174A (es)
AR (1) AR028732A1 (es)
AU (1) AU2001266860A1 (es)
BR (1) BR0111571A (es)
CA (1) CA2412979A1 (es)
CZ (1) CZ20023931A3 (es)
EC (1) ECSP024386A (es)
HU (1) HUP0302955A3 (es)
IL (1) IL152718A0 (es)
MX (1) MXPA02012415A (es)
NO (1) NO20026011L (es)
PE (1) PE20011364A1 (es)
PL (1) PL362477A1 (es)
UY (1) UY26776A1 (es)
WO (1) WO2001096311A2 (es)
ZA (1) ZA200210102B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
KR20030069983A (ko) * 2000-08-15 2003-08-27 화이자 프로덕츠 인코포레이티드 치료용 조합물
HUP0401724A2 (hu) * 2001-06-06 2004-12-28 Bristol-Myers Squibb Co. Eljárás királis diol-szulfon és dihidroxi-sav típusú HMG CoA reduktáz inhibitorok előállítására
ATE360417T1 (de) 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen
WO2003024395A2 (en) 2001-09-14 2003-03-27 Tularik Inc. Linked biaryl compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
BR0312778A (pt) * 2002-07-18 2005-05-03 Sankyo Co Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
US7585866B2 (en) * 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
WO2004033446A1 (en) * 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
CA2526730A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
WO2005087226A1 (en) * 2004-03-05 2005-09-22 Eisai Co., Ltd. Cadasil treatment with cholinesterase inhibitors
JP2007532624A (ja) * 2004-04-14 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルツハイマー病の治療のための療法組合せ
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20070112050A1 (en) * 2005-04-12 2007-05-17 Psivida Inc. HMGCoA reductase inhibitor combinations and uses thereof
JP2009503075A (ja) * 2005-08-01 2009-01-29 シヴィダ・インコーポレイテッド ＨＭＧＣｏＡ還元酵素インヒビターコドラッグ及びその使用
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2007091338A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
EP1996939B1 (en) * 2006-02-27 2014-03-26 Targeted Molecular Diagnostics, LLC Methods for predicting cardiac toxicity before and upon treatment with tyrosine kinase inhibitors
CA2645281A1 (en) * 2006-03-29 2007-10-04 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008059519A2 (en) * 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
KR100900044B1 (ko) * 2007-07-05 2009-06-01 한국식품연구원 3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101104335B1 (ko) * 2009-03-06 2012-01-16 가톨릭대학교 산학협력단 알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9056134B2 (en) * 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
CN103313984B (zh) * 2011-01-18 2016-01-13 中化帝斯曼制药有限公司荷兰公司 甲基四唑硫化物和砜
WO2012098049A1 (en) 2011-01-18 2012-07-26 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of statins in the presence of base
US9150562B2 (en) 2011-01-18 2015-10-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of diol sulfones
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
CN107296798A (zh) 2011-10-28 2017-10-27 维塔利斯公司 抗发红组合物
EP2788342B1 (en) 2011-12-09 2018-01-24 DSM Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of a statin precursor
WO2013083719A1 (en) 2011-12-09 2013-06-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of a thioprecursor for statins
JP6041985B2 (ja) * 2012-06-08 2016-12-14 ミレ ファイン ケミカル カンパニー リミテッド 結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN112159403B (zh) 2020-09-30 2022-04-15 复旦大学 一种用于合成他汀类药物的关键中间体的制备方法
CN114394961A (zh) * 2021-12-24 2022-04-26 江苏阿尔法药业股份有限公司 用臭氧做氧化剂制备瑞舒伐他汀钙中间体的方法
CN114213350B (zh) * 2021-12-29 2024-03-19 江苏福瑞康泰药业有限公司 一种他汀类药物中间体的制备方法
CN114437052B (zh) * 2021-12-31 2024-03-29 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种利用连续流微通道反应器合成他汀类药物中间体的方法
CN114601039A (zh) * 2022-03-16 2022-06-10 江苏省农业科学院 一种提高热应激下绵羊发情率和受胎率的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
EP1294696A2 (en) 2003-03-26
BR0111571A (pt) 2003-07-01
AU2001266860A1 (en) 2001-12-24
PL362477A1 (en) 2004-11-02
HUP0302955A3 (en) 2005-08-29
WO2001096311A3 (en) 2002-07-11
CZ20023931A3 (cs) 2003-03-12
CA2412979A1 (en) 2001-12-20
NO20026011L (no) 2003-02-12
WO2001096311A2 (en) 2001-12-20
PE20011364A1 (es) 2002-02-27
US20020028826A1 (en) 2002-03-07
NO20026011D0 (no) 2002-12-13
MXPA02012415A (es) 2003-06-06
JP2004503541A (ja) 2004-02-05
ECSP024386A (es) 2003-03-10
IL152718A0 (en) 2003-06-24
ZA200210102B (en) 2004-03-12
KR20030010720A (ko) 2003-02-05
UY26776A1 (es) 2002-01-31
HUP0302955A2 (hu) 2003-12-29
CN1436174A (zh) 2003-08-13

Similar Documents

Publication Publication Date Title
AR028732A1 (es) Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.
AR030700A1 (es) Compuestos inhibidores de la reductasa hmg-coa y las composiciones y combinaciones farmaceuticas que las contienen
AR045828A1 (es) Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa
DE69425615D1 (de) Kondensierte sieben- oder achtgliedrige heterocyclische Verbindungen verwendbar als Squaleninhibitoren
NZ337118A (en) 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same useful in treating or preventing arteriosclerotic and/or hyper-lipemia disease, pancreatitis, obesity, hypercholesterolemia and hypertriglyceridemia.
ECSP034534A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
EA200601660A1 (ru) Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
BR0010304A (pt) Derivados de piperazina úteis como antagonistas do ccr5
BR0113200A (pt) Combinação terapêutica
AR038882A1 (es) Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
DK1263730T3 (da) Aminderivater til behandling af apoptose
CL2004000965A1 (es) Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com
MXPA06001094A (es) Compuestos quimicos.
HUP0100184A2 (hu) Szubsztituált 2-(benzil-amino)-2-fenil-acetamid-vegyületek és ezeket tartalmazó gyógyszerkészítmények
BR0309668A (pt) Imidazolinilmetil aralquilsulfonamidas
SE9001269L (sv) 2-substituerade n,n'-ditrimetoxbensoylpiperaziner, en framstaellningsmetod foer dessa samt terapeutiska kompositioner som innehaaller dem
AR018077A1 (es) Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol
ATE253565T1 (de) Inhibitoren der cholesterolesterase
PE20021007A1 (es) Derivados de 1,3-diaminopropano sustituidos, procedimientos para su preparacion, medicamentos y composiciones farmaceuticas que los contienen
SE9401965D0 (sv) New compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal